Table 3.
Qualitative variables of the subjects as a function of the diagnosis of premorbid metabolic syndrome based on the WHO proposal
| Total n = 621 | Pre-MetS n = 136 | Non Pre-MetS n = 485 | p | ||
|---|---|---|---|---|---|
| Sex |
♂ |
48.0 (44.1-51.9) |
55.9 (47.6-64.2) |
45.8 (41.4-50.2) |
|
| |
♀ |
52.0 (48.1-55.9) |
44.1 (35.8-52.4) |
54.2 (49.8-58.6) |
<0.001 |
| AC drugs |
|
30.0 (26.4-33.6) |
49.3 (40.9-57.7) |
24.5 (20.7-28.3) |
<0.001 |
| AH drugs |
|
32.7 (29.0-36.4) |
49.3 (40.9-57.7) |
28.0 (24.0-32.0) |
<0.001 |
| Smoking habit |
|
30.1 (26.5-33.7) |
27.9 (20.4-35.4) |
30.7 (26.6-34.8) |
0.597 |
| Physical inactivity |
|
58.9 (55.0-62.8) |
69.9 (62.2-77.6) |
55.9 (51.5-60.3) |
0.004 |
| BMI |
<25 |
42.4 (38.5-46.3) |
12.5 (7.0-18.1) |
50.7 (46.6-55.2) |
|
| ≥25 | 57.6 (53.7-61.5) | 87.5 (81.9-93.1) | 49.3 (44.9-53.7) | <0.001 |
p ≤ 0.05 is considered to be statistically significant.
Data are expressed as percentages (95% Confidence Interval).
Pre-MetS premorbid metabolic syndrome; AC drugs: pharmacological treatment of hypercholesterolemia or hypertriglyceridemia; AH Drugs: pharmacological treatment of hypertension.